ArriVent BioPharma
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, ArriVent BioPharma sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
ArriVent BioPharma: 4 sponsored US clinical trials, 2 recruiting.
ArriVent BioPharma sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Non-Small-Cell Lung Cancer, with 3 trials.
Upper-quartile sponsor footprint
ArriVent BioPharma sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the ArriVent BioPharma pipeline
2 recruiting of 4 indexed (50% open).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Advanced Non-Small-Cell Lung Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ArriVent BioPharma: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
ArriVent BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this ArriVent BioPharma page
4 registered trials is a research-attention snapshot, not an endorsement of ArriVent BioPharma or any single study.
- 2 of ArriVent BioPharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Non-Small-Cell Lung Cancer is the condition ArriVent BioPharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Non-Small-Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ArriVent BioPharma pipeline card: 4 registered trials from official public datasets.Report a data error.